Accessibility, cost of game-changing obesity drugs problematic - MJA Insight

The barriers to accessing medications for obesity represent an important equity issue

THE off-label use of semaglutide (Ozempic; Novo Nordisk) for the treatment of obesity has been blamed for a recent supply shortage of the medication, which is indicated for type 2 diabetes. However, … [+9795 chars]

full article...